Autoimmune hemolytic anemia occurs due to an interaction of IgG antibodies with protein antigens expressed on red blood corpuscles. Glucocorticoids are the mainstay of treatment for autoimmune hemolytic anemia. For patients not responding to initial therapy, other agents such as rituximab, immunosuppressive therapy, or splenectomy are considered. When refractory to these treatment options, alemtuzumab is an alternative agent. However, long-term outcomes of patients supporting its use are lacking. We present three patients with refractory autoimmune hemolytic anemia treated with alemtuzumab.
ParkSH. Diagnosis and treatment of autoimmune hemolytic anemia: classic approach and recent advances. Blood Res2016; 51: 69–71.
2.
ZanellaABarcelliniW. Treatment of autoimmune hemolytic anemias. Haematologica2014; 99: 1547–1547.
3.
MauroFRFoaRCerrettiRet al.Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood2000; 95: 2786–2786.
4.
OsterborgAKarlssonCLundinJ. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia. Curr Hematol Malig Rep2009; 4: 47–53.
5.
BarcelliniW. Current treatment strategies in autoimmune hemolytic disorders. Expert Rev Hematol2015; 8: 681–691.
6.
WillisFMarshJCBevanDHet al.The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol2001; 114: 891–898.
7.
CheungWWHwangGYTseEet al.Alemtuzumab induced complete remission of autoimmune hemolytic anemia refractory to corticosteroids, splenectomy and rituximab. Haematologica2006; 91: Ecr13–Ecr13.
8.
RodonPBretonPCouroubleG. Treatment of pure red cell aplasia and autoimmune haemolytic anaemia in chronic lymphocytic leukaemia with Campath-1H. Eur J Haematol2003; 70: 319–321.
9.
RoyerBVaidaIEtienneAet al.Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab. Leukemia2007; 21: 1841–1842. author reply 2–3.
10.
LundinJKarlssonCCelsingF. Alemtuzumab therapy for severe autoimmune hemolysis in a patient with B-cell chronic lymphocytic leukemia. Med Oncol2006; 23: 137–139.
11.
KarlssonCHanssonLCelsingFet al.Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody). Leukemia2007; 21: 511–514.
12.
LaurentiLTarnaniMEfremovDGet al.Efficacy and safety of low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia. Leukemia2007; 21: 1819–1821. author reply 21.
